MAB3070
Anti-Granzyme B Antibody, clone GrB-7
culture supernatant, clone GrB-7, Chemicon®
Sign Into View Organizational & Contract Pricing
All Photos(1)
Synonym(s):
Anti-Anti-C11, Anti-Anti-CCPI, Anti-Anti-CGL-1, Anti-Anti-CGL1, Anti-Anti-CSP-B, Anti-Anti-CSPB, Anti-Anti-CTLA1, Anti-Anti-CTSGL1, Anti-Anti-HLP, Anti-Anti-SECT
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
mouse
Quality Level
antibody form
culture supernatant
antibody product type
primary antibodies
clone
GrB-7, monoclonal
species reactivity
human
manufacturer/tradename
Chemicon®
technique(s)
immunohistochemistry: suitable (paraffin)
western blot: suitable
isotype
IgG2a
NCBI accession no.
UniProt accession no.
shipped in
dry ice
target post-translational modification
unmodified
Gene Information
human ... GZMB(3002)
Specificity
Monoclonal antibody recognizes the 33 kDa granzyme B.
Reacts specifically with human serine protease granzyme B. Does not cross-react with human granzyme A. Granzyme B localizes in cytoplasmic granules and can be used as a marker for NK cells and activated cytotoxic T-cells.
Reacts specifically with human serine protease granzyme B. Does not cross-react with human granzyme A. Granzyme B localizes in cytoplasmic granules and can be used as a marker for NK cells and activated cytotoxic T-cells.
Application
Detect Granzyme B using this Anti-Granzyme B Antibody, clone GrB-7 validated for use in WB, IH(P).
Immunoblotting
Immunohistochemistry of granzyme B-expressing lymphocytes in sublimate sections and formalin-fixed paraffin-embedded tissues (1:20 dilution). Does not react with other cell types. Cannot be used on frozen sections.
Note on the use of MAB3070 on paraffin sections:
Tissue slides should be pretreated with an antigen retrieval method, such as treatment with 0.1M sodium citrate for 10 min at 100°C. A working dilution of 1:20 is advised, but optimal working dilutions must be determined by end user.
Immunohistochemistry of granzyme B-expressing lymphocytes in sublimate sections and formalin-fixed paraffin-embedded tissues (1:20 dilution). Does not react with other cell types. Cannot be used on frozen sections.
Note on the use of MAB3070 on paraffin sections:
Tissue slides should be pretreated with an antigen retrieval method, such as treatment with 0.1M sodium citrate for 10 min at 100°C. A working dilution of 1:20 is advised, but optimal working dilutions must be determined by end user.
Research Category
Apoptosis & Cancer
Metabolism
Apoptosis & Cancer
Metabolism
Research Sub Category
Apoptosis - Additional
Enzymes & Biochemistry
Apoptosis - Additional
Enzymes & Biochemistry
Physical form
Liquid
Storage and Stability
Maintain at -20°C for up to 12 months.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
WGK
WGK 2
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Milan Fiala et al.
Journal of neuroinflammation, 7, 76-76 (2010-11-11)
The contribution of inflammation to neurodegenerative diseases is increasingly recognized, but the role of inflammation in sporadic amyotrophic lateral sclerosis (sALS) is not well understood and no animal model is available. We used enzyme-linked immunosorbent assays (ELISAs) to measure the
Mingyao Meng et al.
The Journal of biological chemistry, 293(51), 19600-19612 (2018-10-20)
Several clinical immunotherapy trials with cytokine-induced killer (CIK) cells have been reported. However, molecular evidence of cell expansion, acquisition of tumor cytotoxicity, and safety of CIK cells is required before putting them to clinical use. Here, we performed dynamic transcriptomic
Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma.
Shintaro Yokoyama et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 22(18), 4727-4734 (2016-05-12)
The immune checkpoint of the programmed death 1/programmed death ligand 1 (PD-1/PD-L1) pathway is believed to play an important role in evasion of host antitumor immune surveillance in various malignancies; however, little is known about its role in thymic carcinoma.
Jenny Bulgarelli et al.
Frontiers in immunology, 10, 2353-2353 (2019-10-28)
Dendritic cell (DC)-based vaccination effectively induces anti-tumor immunity, although in the majority of cases this does not translate into a durable clinical response. However, DC vaccination is characterized by a robust safety profile, making this treatment a potential candidate for
Yong Zeng et al.
Molecular therapy. Methods & clinical development, 18, 422-427 (2020-07-23)
Intravitreal administration for human adeno-associated vector (AAV) delivery is easier and less traumatic to ocular tissues than subretinal injection, but it gives limited retinal transduction. AAV vectors are large (about 4,000 kDa) compared with most intraocular drugs, such as ranibizumab (48 kDa)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service